Sarepta Therapeutics (SRPT) PT Raised to $96 at Nomura/Instinet on 4Q Beat; 'Pipeline Registration Path & DMD Gene Therapies Emerge in 2018'

Nomura/Instinet raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $96.00 (from $84.00) while maintaining a Buy rating, following the company's fourth quarter earnings report.

Analyst Christopher Marai notes a positive outlook on the shares, as SRPT reported fourth quarter earning per share and revenues above consensus projections, while management affirmed FY18 guidance of $295-$305 million.

You May Also Be Interested In

• Benchmark Starts Boyd Gaming (BYD) at Buy
• Scotiabank Resumes Parex Resources Inc. (PXT:CN) (PARXF) at Sector Perform
• Wolfe Research Upgrades Kimco (KIM) to Outperform